Tezepelumab is a monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), a cytokine involved in the initiation and maintenance of allergic and inflammatory responses. Tezepelumab binds to TSLP and inhibits its interaction with its receptor complex, thereby blocking the downstream signaling pathways that lead to inflammation and the activation of various immune cells involved in allergic responses. It is indicated for the treatment of severe asthma. Specifically, tezepelumab is used in patients with uncontrolled asthma despite treatment with high-dose inhaled corticosteroids and other asthma controllers. It helps to reduce asthma exacerbations and improve lung function.